If you or someone in your family has just been told there is a cancer, this guide is for you. It walks through the six most commonly diagnosed cancers in Africa, what treatment for each one actually involves, what is realistically available at home, and what changes when you travel to India for care. The intention is to give you enough information to ask the right questions and make decisions calmly, one step at a time.
The numbers, first. According to the 2022 Global Cancer Observatory (GLOBOCAN) estimates from the International Agency for Research on Cancer, around 1.15 million new cancer cases are diagnosed in Africa every year, with 754,000 cancer deaths. Five cancers, breast, cervical, prostate, liver and colorectal, account for almost half of all cases on the continent. Egypt, Nigeria, South Africa, Ethiopia and Morocco together carry the greatest share of the burden.
The harder truth running through almost every cancer in Africa is the same: the disease is curable far more often than it is cured, and what stands between the two is mostly time. Most cancers in sub-Saharan Africa are diagnosed late, at stage III or stage IV, when treatment options narrow sharply and survival drops. A multi-country study of cervical cancer survival across 11 sub-Saharan African countries reported 5-year survival of around 33 per cent overall.
Why patients travel to India
India is now one of the most common destinations for African oncology patients for three reasons. First, capacity: leading Indian hospitals, including Apollo, Fortis Memorial Research Institute, Medanta and BLK-Max, run high-volume oncology programmes accredited by Joint Commission International (JCI), the same body that accredits hospitals in the United States and Europe. Second, the full pathway is available in one place: surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy and stem cell or bone marrow transplant where indicated, all under one multidisciplinary team. Third, cost: cancer treatment in India typically runs 60 to 70 per cent below comparable Western prices, which puts curative treatment within reach for families who would otherwise have to settle for palliation.
India is not the right answer for every patient. For early-stage cancers where local treatment is genuinely available and starting on time, staying at home is often best. India becomes important when local oncology capacity is delayed, incomplete or unavailable for the specific cancer and stage.
1. Breast cancer: the most common cancer in African women
Breast cancer is the most commonly diagnosed cancer in Africa across both sexes, with around 198,500 new cases and 91,300 deaths in 2022. Nigeria reported the highest case numbers and deaths of any African country (32,278 cases, 16,332 deaths). Breast cancer is the most common cancer in women in 32 of 54 African countries.
The clinical problem in Africa is that breast cancer often presents late. The cancer can be biologically aggressive, and survival depends heavily on stage at diagnosis. In Nigeria, between 72 and 89 per cent of patients pay for breast cancer care out of pocket, which itself drives delays in seeking treatment. Where care is available locally, it may be incomplete: surgery may be available, but radiotherapy machines may have long waits or be located far from the patient, and HER2-targeted therapy or hormone therapy may not be reliably stocked.
Treatment in India follows international protocols: imaging and biopsy to confirm stage and biology (ER, PR and HER2 status), surgery (lumpectomy or mastectomy), reconstruction where appropriate, radiotherapy, chemotherapy, hormone therapy for ER-positive disease, and HER2-targeted therapy (trastuzumab and others) for HER2-positive disease. The MediVenza breast cancer treatment package starts from $5,000 USD for surgery, with full pathways including chemotherapy and reconstruction costed transparently before travel. A typical full-pathway stay is 6 to 12 weeks.
2. Cervical cancer: the leading cause of cancer death in African women
Cervical cancer is the second most commonly diagnosed cancer in African women, with 125,699 new cases and 80,614 deaths in 2022. It is the leading cause of cancer death in women in sub-Saharan Africa. Of the 20 countries worldwide with the highest cervical cancer burden, 18 are in the World Health Organization's Africa region. Africa accounts for 23 per cent of global cervical cancer mortality despite holding only 16 per cent of the world's female population.
Almost all cervical cancer is caused by persistent infection with high-risk human papillomavirus (HPV). It is one of the few cancers that is largely preventable through HPV vaccination and treatable with high cure rates if caught early. The reason mortality is so high in Africa is the combination of low screening coverage, late presentation and limited radiotherapy capacity. In sub-Saharan Africa, around 65 per cent of cervical cancer patients are diagnosed at stage III or IV. HIV co-infection accelerates the disease in many patients and complicates treatment.
Cervical cancer treatment depends heavily on stage. Early-stage disease is treated with surgery (often radical hysterectomy with lymph node dissection) or, in selected cases, with fertility-sparing approaches. Advanced disease requires chemoradiotherapy, the combination of external beam radiotherapy with concurrent platinum-based chemotherapy, often followed by brachytherapy. Recurrent and metastatic disease is now treated with immune checkpoint inhibitors such as pembrolizumab where available. India performs the full pathway at JCI-accredited centres, with brachytherapy and IMRT (intensity-modulated radiotherapy) routinely available, which is often the bottleneck at home.
3. Prostate cancer: the leading cancer in African men
Prostate cancer is the most commonly diagnosed cancer in African men, with 103,050 new cases and 55,744 deaths in 2022. It is also the leading cause of cancer death in men across sub-Saharan Africa and the Caribbean. In Nigeria, prostate cancer accounts for around 37.5 per cent of new male cancer cases. Men of African ancestry have higher incidence and more aggressive disease than men of European descent, partly explained by genetic and biological factors and partly by late diagnosis.
The clinical problem mirrors what happens with breast and cervical cancer: most patients present at advanced stages. A multi-country sub-Saharan African study found that 45 per cent of prostate cancer patients had stage IV disease at diagnosis and only around 24 per cent had stage I or II disease. In one Nigerian centre, orchidectomy (surgical castration) remained the most common first-line treatment because newer therapies were unavailable or unaffordable.
Treatment options for prostate cancer include active surveillance for low-risk disease, radical prostatectomy (often robotically assisted with the da Vinci system at Indian centres), external beam radiotherapy, brachytherapy, and androgen deprivation therapy. For advanced disease, chemotherapy, abiraterone, enzalutamide, and PSMA-targeted radioligand therapy are available at major Indian centres. The combination of skilled robotic surgery, modern radiotherapy and access to newer agents is what most patients are travelling for.
4. Liver cancer: the third leading cause of cancer death in Africa
Liver cancer is the fourth most common cancer in Africa by incidence (73,844 new cases in 2022) but the third leading cause of cancer death (70,315 deaths), reflecting a mortality-to-incidence ratio of around 0.95, almost as deadly as it is common. Liver cancer is the leading cause of cancer death in men in 24 countries worldwide, including Egypt, Senegal and Ghana.
Two factors drive liver cancer in Africa. The first is chronic hepatitis B infection, still highly prevalent in much of sub-Saharan Africa despite expanding vaccination programmes. The second is aflatoxin exposure from contaminated stored food crops, which combines with hepatitis B to multiply liver cancer risk. The most common form of liver cancer is hepatocellular carcinoma (HCC).
Treatment options depend on stage and on the underlying liver function. Early HCC can be treated with surgical resection, ablation (radiofrequency or microwave), or, in selected cases, liver transplantation, which is curative when criteria are met. Intermediate-stage HCC is often treated with TACE (transarterial chemoembolisation) or TARE (radioembolisation with Yttrium-90), both available at MediVenza partner hospitals. Advanced HCC is treated with systemic therapy including immunotherapy (atezolizumab plus bevacizumab) and tyrosine kinase inhibitors (sorafenib, lenvatinib). Where transplantation is the right answer, the MediVenza liver transplant pathway starts from $22,000 USD; living donor liver transplant for foreign patients is governed by India's Transplantation of Human Organs and Tissues Act and requires a near-relative donor.
5. Colorectal cancer: the fifth most common across Africa
Colorectal cancer (cancer of the colon or rectum) is the fifth most commonly diagnosed cancer in Africa, with 70,428 new cases and 46,087 deaths in 2022. It is among the top 10 cancers in all 54 African countries. Incidence is rising in many African countries as diets change. Mortality-to-incidence ratio in Africa is around 0.65, considerably worse than in high-income countries, again reflecting late diagnosis.
Most colorectal cancers begin as benign polyps and become cancerous over years. Where colonoscopy screening is available, many cancers are caught early or prevented entirely. Symptoms include changes in bowel habit, blood in the stool, unexplained weight loss, and iron-deficiency anaemia. Treatment depends on stage. Early disease is removed by surgical resection, often laparoscopically or robotically, sometimes during colonoscopy itself for the smallest cancers. More advanced cancers require formal bowel resection plus chemotherapy. Rectal cancers are usually treated with chemoradiotherapy first, then surgery. Liver and lung metastases, where present and limited, are increasingly resected for cure rather than just managed palliatively. Indian centres routinely perform laparoscopic and robotic colorectal cancer surgery, with full chemotherapy and targeted therapy options available.
6. Non-Hodgkin lymphoma: the sixth most common
Non-Hodgkin lymphoma (NHL) is the sixth most commonly diagnosed cancer in Africa, with 50,497 new cases and 30,758 deaths in 2022. NHL is a cancer of the lymphatic system and includes many subtypes, the most common being diffuse large B-cell lymphoma (DLBCL). HIV infection significantly increases the risk of certain lymphomas, which is part of why NHL incidence in sub-Saharan Africa runs higher in some age groups than would otherwise be expected.
NHL presents most often with painless swollen lymph nodes (in the neck, armpit or groin), unexplained weight loss, fevers and night sweats. Diagnosis requires a lymph node biopsy, immunohistochemistry to identify the subtype, and PET-CT imaging for staging. Treatment is primarily chemotherapy, most commonly the R-CHOP regimen (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone) for DLBCL, given over six cycles. For aggressive or relapsed lymphomas, autologous bone marrow transplant or CAR-T cell therapy may be required. Indian centres run high-volume haemato-oncology programmes with all of these capabilities; Apollo, Fortis and BLK-Max have established CAR-T and bone marrow transplant units. The MediVenza network covers the full oncology pathway including bone marrow transplant for patients who need it.
How treatment in India actually works for African patients
The process is sequential and predictable. It usually unfolds in this order:
Send your medical reports. The hospital's tumour board reviews your imaging, biopsy and any prior treatment, and produces a written treatment plan with a costed estimate. MediVenza coordinates this within 24 to 48 hours.
The hospital generates a Visa Invitation Letter. This goes through India's government Medical and Ayush Visa Portal. You apply for an Indian Medical Visa: e-Medical Visa (60 days, triple entry) for shorter pathways, or Regular Medical Visa (up to 1 year, triple entry) for longer pathways such as transplants and full chemotherapy programmes.
Vaccinations and pre-departure checks. Yellow Fever vaccination is mandatory at least 10 days before travel. Oral Polio Vaccination is mandatory at least 4 weeks before travel for travellers from Nigeria, Ghana, Ethiopia, Kenya and several other African countries. Confirm specifics with your nearest Indian High Commission.
Travel and accommodation. You can bring up to two attendants on M-X Medical Attendant Visas (close family). MediVenza arranges airport pickup, hospital admission, and accommodation suited to the length of stay.
Treatment begins. A typical breast or colorectal cancer pathway is 6 to 12 weeks. Cervical cancer chemoradiotherapy is around 7 to 9 weeks. Liver transplant requires 3 to 6 months for the patient and 4 to 6 weeks for the donor. Some patients return home for ongoing chemotherapy after the surgical and initial chemo phase, with the regimen sent to a local oncologist.
Honest cost framing
Treatment | India starting price | Typical Western equivalent |
|---|---|---|
Breast cancer surgery + adjuvant therapy | From $5,000 USD (surgery package) | $25,000 to $80,000+ |
Cervical cancer chemoradiotherapy | Varies by stage; typically $8,000 to $15,000 USD | $30,000 to $60,000+ |
Prostate cancer (robotic prostatectomy) | $6,000 to $12,000 USD | $30,000 to $60,000+ |
Liver transplant | From $22,000 USD | $300,000 to $500,000+ |
Colorectal cancer resection + chemo | $6,000 to $15,000 USD | $40,000 to $80,000+ |
Non-Hodgkin lymphoma chemotherapy (R-CHOP, 6 cycles) | Around $6,000 to $10,000 USD | $50,000 to $100,000+ |
These figures cover the medical components only. International flights, accommodation outside the hospital, attendant visas, immunotherapy or targeted therapy drugs, and any complications requiring extended ICU care are typically separate. Currency rates fluctuate; check current USD-to-local-currency rates before budgeting. MediVenza provides a written, itemised estimate before you commit to travel.
Cancer treatment is one of the hardest decisions a family ever has to make. The most important thing is not to delay further while you weigh the options. Send the reports, get a written treatment plan, and decide from a position of information rather than fear. MediVenza coordinates everything from the initial review through to discharge and ongoing follow-up at home. You can reach the team via the contact page or on WhatsApp at +91 98996 55596 in any time zone, and there is no commitment to travel; many families use the assessment to clarify their options first.
